Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 21Terminated 5Recruiting 3Withdrawn 2Unknown 1Suspended 1Enrolling by invitation 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 241Carcinoma, Non-Small-Cell Lung 56Carcinoma, Renal Cell 40Skin Neoplasms 39Uveal Melanoma 31Squamous Cell Carcinoma of Head and Neck 30Neoplasms 30Colorectal Neoplasms 27Sarcoma 25Neoplasm Metastasis 25Carcinoma, Merkel Cell 24Ovarian Neoplasms 23Lung Neoplasms 22Stomach Neoplasms 21Carcinoma, Basal Cell 21Breast Neoplasms 20Head and Neck Neoplasms 18Esophageal Neoplasms 16Uterine Cervical Neoplasms 15Pancreatic Neoplasms 15Carcinoma, Hepatocellular 15Lymphoma, T-Cell, Cutaneous 14Urinary Bladder Neoplasms 13Triple Negative Breast Neoplasms 13Prostatic Neoplasms 13Carcinoma, Transitional Cell 13Brain Neoplasms 13Thyroid Neoplasms 11Small Cell Lung Carcinoma 10Mycosis Fungoides 10

Interventions

IPI-926 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Basal Cell Nevus Syndrome × Dermatologic × Clear all
NCT06050122 2025-10-14

Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome

Sol-Gel Technologies, Ltd.

Phase 3 Active not recruiting
140 enrolled
Dermatologic

Basal Cell Nevus Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡